Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14591472 | 0.89 | MC4R (0.43) | MC4RMC3R | |
| SCHEMBL14591448 | 0.87 | MC4R (0.68) | MC4RMC3R | |
| SCHEMBL5360371 | 0.82 | MC4R (0.60) | MC4RMC3R | |
| SCHEMBL14591467 | 0.82 | MC4R (0.60) | MC4RMC3R | |
| SCHEMBL14355687 | 0.81 | MC4R (0.53) | MC4R | |
| SCHEMBL14356068 | 0.81 | MC4R (0.53) | MC4R | |
| SCHEMBL13790223 | 0.81 | MC4R (0.53) | MC4R | |
| SCHEMBL14591293 | 0.80 | MC4R (0.65) | MC4RMC3R | |
| SCHEMBL14591469 | 0.80 | MC4R (0.48) | MC4R | |
| SCHEMBL5356851 | 0.80 | AKT1 (0.50) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | MC1R, MC4R, MC5R | MC4R 2/4885MC3R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.